Affi­ni-T to close Seat­tle lab as it con­cen­trates in Boston, preps two IND fil­ings in next two months

Affi­ni-T Ther­a­peu­tics is clos­ing its Seat­tle site at the end of Au­gust, CEO and co-founder Jak Knowles con­firmed to End­points News Wednes­day af­ter­noon.

The biotech has of­fered some of its 17 Seat­tle-based em­ploy­ees the op­tion to re­lo­cate to its Boston-area op­er­a­tions, where it has more than 40,000 square feet of lab space, Knowles said. Out­side of Seat­tle, Affi­ni-T has about 80 em­ploy­ees, the com­pa­ny said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER